TECVAYLI + DARZALEX FASPRO FDA Approval Johnson & Johnson (NYSE: JNJ)’s Phase 3 MajesTEC-3 data show an 83% reduction in risk of disease progression or death, with 83.3% of patients alive at three years reshaping the multiple myeloma treatment paradigm … Continue reading →

FDA Orphan Drug Designation for GENFIT’s G1090N With no approved therapy for Acute-on-Chronic Liver Failure (ACLF) and approximately 62K cases recorded across major markets, this FDA designation of GENFIT’s G1090N signals an accelerating race to address one of hepatology’s most … Continue reading →

FDA Grants Priority Review to ENHERTU in Post-Neoadjuvant HER2-Positive Early Breast Cancer Phase III DESTINY-Breast05 data shows a 53% reduction in invasive disease recurrence or death vs. T-DM1, redefining the standard of care for nearly 16,000 annual post-neoadjuvant patients in … Continue reading →

FDA Accepts NDA for Rusfertide and Grants Priority Review in Polycythemia Vera Takeda and Protagonist Therapeutics’ first-in-class hepcidin mimetic moves closer to market as FDA sets Q3 2026 PDUFA date; DelveInsight’s Polycythemia Vera Market Report tracks the full competitive and … Continue reading →

Minimally Invasive Surgical Devices Market Leading minimally invasive surgical devices companies include Abbott, Olympus, Intuitive Surgical Inc., Stryker, JOHNSON & JOHNSON MEDICAL DEVICES COMPANIES, Medtronic, Boston Scientific Corporation, CONMED Corporation, KARL STORZ GmbH, CooperSurgical, Inc., Cook, AngioDynamics, FUJIFILM Corporation, Symmetry … Continue reading →